1. Search Result
Search Result
Isoforms Recommended: CDK19
Results for "

CDK19

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Fluorescent Dye

3

Recombinant Proteins

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-122586

    CDK Interleukin Related Inflammation/Immunology
    BRD6989, an analog of the natural product cortistatin A (dCA), inhibits CDK8 and upregulates IL-10. BRD6989 selectively binds a complex of CDK8 with an IC50 of ~200 nM. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 complexes .
    BRD6989
  • HY-111518
    JH-XI-10-02
    2 Publications Verification

    PROTACs CDK Cancer
    JH-XI-10-02 is a PROTAC connected by ligands for Cereblon and CDK. JH-XI-10-02 is a highly potent and selective PROTAC CDK8 degrader, with an IC50 of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19 .
    JH-XI-10-02
  • HY-111388B
    Romaciclib hydrochloride
    5+ Cited Publications

    SEL120-34A hydrochloride

    CDK Cancer
    SEL120-34A hydrochloride is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
    Romaciclib hydrochloride
  • HY-101800
    Senexin B
    1 Publications Verification

    SNX2-1-165; BCD-115

    CDK Cancer
    Senexin B (SNX2-1-165; BCD-115) is a potent, highly water-soluble and bioavailable CDK8/19 inhibitor, with Kds of 140 nM for CDK8 and 80 nM for CDK19.
    Senexin B
  • HY-12681
    CCT251545
    2 Publications Verification

    Wnt Cancer
    CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with an IC50 of 5 nM in 7dF3 cells . CCT251545 is a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease .
    CCT251545
  • HY-D2311

    CDK Cancer
    CDK19 Probe 1 (Compound 10c) is a CDK19 inhibitor (IC50: 1.01 μM) and can be used for cancer research .
    CDK19 Probe 1
  • HY-RS02371

    Small Interfering RNA (siRNA) CDK Others

    CDK19 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK19 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CDK19 Human Pre-designed siRNA Set A
    CDK19 Human Pre-designed siRNA Set A
  • HY-RS02372

    Small Interfering RNA (siRNA) CDK Others

    Cdk19 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk19 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk19 Mouse Pre-designed siRNA Set A
    Cdk19 Mouse Pre-designed siRNA Set A
  • HY-RS02373

    Small Interfering RNA (siRNA) CDK Others

    Cdk19 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk19 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk19 Rat Pre-designed siRNA Set A
    Cdk19 Rat Pre-designed siRNA Set A
  • HY-111388

    CDK Cancer
    SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
    SEL120-34A
  • HY-111427

    CDK Cancer
    CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively.
    CDK8/19-IN-1
  • HY-139875
    JH-XVI-178
    1 Publications Verification

    CDK Cancer
    JH-XVI-178 is a highly efficient and selective CDK8/19 inhibitor, with IC50 values of 1 and 2 nM for CDK8 and CDK19, respectively. JH-XVI-178 has a low clearance rate and moderate oral pharmacokinetic properties .
    JH-XVI-178
  • HY-168846

    CDK Inflammation/Immunology
    CDK8/19-IN-3 (compound 3-7) is a potent and selective CDK8 and CDK19 inhibitor. CDK8/19-IN-3 upregulates IL-10 levels. CDK8/19-IN-3 has the potential for the research of inflammatory bowel disease (IBD) .
    CDK8/19-IN-3
  • HY-158377

    CDK STAT Cancer
    CDK8/19-IN-2 (compound 12) is an orally active and potent cyclin-dependent kinase 8/19 (CDK8 and CDK19) inhibitor, with IC50 values of 2.08 and 2.49 nM, respectively. CDK8/19-IN-2 can be used for acute myeloid leukemia (AML), breast cancer, and lymphoma research .
    CDK8/19-IN-2
  • HY-126675A
    AS2863619
    2 Publications Verification

    CDK STAT Inflammation/Immunology
    AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3 + regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene .
    AS2863619
  • HY-111388A
    Romaciclib monohydrochloride
    5+ Cited Publications

    SEL120-34A monohydrochloride

    CDK Cancer
    SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726 . Has anti-tumor activity .
    Romaciclib monohydrochloride
  • HY-126675
    AS2863619 free base
    2 Publications Verification

    CDK STAT Inflammation/Immunology
    AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3 + regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene .
    AS2863619 free base
  • HY-171174

    CDK STAT Wnt Cancer
    CDK8-IN-16 (Compound 51) is an orally active dual inhibitor for CDK8 and CDK19 wih IC50 of 5.1 nM and 5.6 nM. CDK8-IN-16 inhibits the phospho-STAT1 SER727 with an IC50 of 17.9 nM in SW620 cell, inhibits WNT signaling pathway with an IC50 of 7.2 nM in 7dF3 cell. CDK8-IN-16 exhibits good pharmacokinetic characteristics in rat models with an oral bioavailability of 57% .
    CDK8-IN-16
  • HY-156366

    PROTACs Others
    SNX7886 is a potent protac degrader of CDK8/19. SNX7886 degrades CDK 8 and CDK 19 with 90% and 80% degradation in 293 cells, respectively .
    SNX7886
  • HY-15681A

    CDK Cancer
    Senexin A hydrochloride is an inhibitor of CDK8/19 (IC50: 280 nM, CDK8) and an inhibitor downstream of p21 transcription. It only inhibits p21-induced transcription but does not inhibit other biological effects of p21. Senexin A hydrochloride inhibits CMV-GFP induction as well as the p21 stimulatory activity of the consensus NF-κB-dependent promoters .
    Senexin A hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: